HBI-002

Phase 2Small molecule

HHillhurst Biopharmaceuticals, Inc.

HBI-002 is one of 45 small molecule programs targeting Parkinson disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Parkinson DiseaseRecruiting

Parkinson DiseasePhase 2

Recruiting

Competition

Competitive Landscape

92 competitors in Parkinson Disease

#DrugCompanyPhaseTrials

Brintellix

Takeda

Approved

1 2

Aricept

Eisai

Approved

1 3

Exelon

Novartis

Approved

1 4

Northera

Lundbeck

Approved

1 5

Myrbetriq

Astellas

Approved

1 6

Medrol

Pfizer

Approved

1 7

Avelox

Nicorette

Epidiolex

Ritalin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Parkinson Disease

NCT07005180

Clinical

Trials by Indication[1]

Oral1 trial

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

Completed·HHillhurst Biopharmaceuticals, Inc.·Phase 1·NCT03926819·20 enrolled

Parkinson disease1 trial

A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, of HBI-002, an Oral Low-dose Carbon Monoxide (CO) Liquid Drug Product, Administered Daily Over 14 Days in Subjects With Parkinson's Disease (PD)

Recruiting·HHillhurst Biopharmaceuticals, Inc.·Phase 2·NCT07005180·36 enrolled

Anemia, Sickle Cell1 trial

An Open Label Phase 2a Ascending Multiple Dose Safety, Efficacy, and Pharmacokinetic Study of HBI-002 Carbon Monoxide Oral Liquid Drug Product in Adolescents and Adults With Sickle Cell Disease.

Completed·HHillhurst Biopharmaceuticals, Inc.·Phase 2·NCT06144749·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HBI-002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HBI-002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HBI-002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hillhurst Biopharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHillhurst Biopharmaceuticals, Inc.

HBI-002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Oral1 trial

Parkinson disease1 trial

Anemia, Sickle Cell1 trial

References

Drug Info

Quick Facts

Related News